NZ730773A - Treatment of fibrodysplasia ossificans progressiva - Google Patents
Treatment of fibrodysplasia ossificans progressivaInfo
- Publication number
- NZ730773A NZ730773A NZ730773A NZ73077315A NZ730773A NZ 730773 A NZ730773 A NZ 730773A NZ 730773 A NZ730773 A NZ 730773A NZ 73077315 A NZ73077315 A NZ 73077315A NZ 730773 A NZ730773 A NZ 730773A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- nos
- antibody
- light chain
- cdrs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049869P | 2014-09-12 | 2014-09-12 | |
| US201562141775P | 2015-04-01 | 2015-04-01 | |
| PCT/US2015/000100 WO2016039796A2 (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ730773A true NZ730773A (en) | 2022-07-01 |
Family
ID=54207748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ730773A NZ730773A (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20160075772A1 (enExample) |
| EP (2) | EP3604335A1 (enExample) |
| JP (1) | JP6560341B2 (enExample) |
| KR (1) | KR102564079B1 (enExample) |
| CN (1) | CN107106648B (enExample) |
| AU (1) | AU2015315829B2 (enExample) |
| CA (1) | CA2960950C (enExample) |
| CL (2) | CL2017000603A1 (enExample) |
| CY (1) | CY1122188T1 (enExample) |
| DK (1) | DK3191512T3 (enExample) |
| ES (1) | ES2739605T3 (enExample) |
| HR (1) | HRP20191929T1 (enExample) |
| HU (1) | HUE046558T2 (enExample) |
| IL (1) | IL251063B (enExample) |
| LT (1) | LT3191512T (enExample) |
| MA (1) | MA40621B1 (enExample) |
| ME (1) | ME03541B (enExample) |
| MX (1) | MX382026B (enExample) |
| MY (1) | MY179654A (enExample) |
| NZ (1) | NZ730773A (enExample) |
| PL (1) | PL3191512T3 (enExample) |
| PT (1) | PT3191512T (enExample) |
| RS (1) | RS59412B1 (enExample) |
| SG (2) | SG11201701913SA (enExample) |
| SI (1) | SI3191512T1 (enExample) |
| SM (1) | SMT201900584T1 (enExample) |
| TW (1) | TWI688402B (enExample) |
| WO (1) | WO2016039796A2 (enExample) |
| ZA (1) | ZA201702112B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| ES3063092T3 (en) | 2017-06-14 | 2026-04-15 | Kymab Ltd | Use of the extracellular domain of the transferrin receptor 2 for diagnosis and treatment of primary and secondary sclerosing diseases |
| IL276921B2 (en) | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
| CN111836643A (zh) * | 2018-03-05 | 2020-10-27 | 学校法人埼玉医科大学 | 用于治疗或预防异位骨化的药物组合物 |
| SMT202500283T1 (it) | 2018-04-06 | 2025-09-12 | Regeneron Pharma | Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia |
| EP3806885A2 (en) | 2018-06-13 | 2021-04-21 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
| SG11202010891SA (en) | 2018-06-13 | 2020-11-27 | Regeneron Pharma | A rodent model of fibrodysplasia ossificans progressiva |
| CA3108328A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| AU2019364415A1 (en) * | 2018-10-23 | 2021-05-20 | Keros Therapeutics, Inc. | ALK2 antibodies and methods of use thereof |
| CN113195532B (zh) * | 2018-12-18 | 2025-04-11 | 瑞泽恩制药公司 | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 |
| IL294611B1 (en) * | 2020-01-08 | 2026-05-01 | Regeneron Pharma | Treatment of fibrodysplasia ossificans progressive |
| WO2021142260A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
| US11945872B2 (en) * | 2020-02-11 | 2024-04-02 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| EP4168038A1 (en) * | 2020-06-18 | 2023-04-26 | Regeneron Pharmaceuticals, Inc. | Activin a antibody formulations and methods of use thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| CA3197104A1 (en) * | 2020-11-11 | 2022-05-19 | Hq Han | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
| CN119529092A (zh) * | 2021-09-03 | 2025-02-28 | 来凯医药科技(上海)有限公司 | 抗acvr2a抗体及其用途 |
| CN121127502A (zh) * | 2023-05-15 | 2025-12-12 | 宜明凯尔生物医药技术(上海)有限公司 | 用于治疗肺高压的重组融合蛋白 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| JP4906094B2 (ja) | 2004-01-16 | 2012-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レセプターを活性化し得る融合ポリペプチド |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8859752B2 (en) * | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| CN101627055A (zh) * | 2006-09-05 | 2010-01-13 | 梅达雷克斯公司 | 骨形成蛋白及其受体的抗体以及它们的使用方法 |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| JP5270913B2 (ja) | 2007-12-26 | 2013-08-21 | サンゴバン・ティーエム株式会社 | 高電気抵抗高ジルコニア鋳造耐火物 |
| EP2265603B1 (en) * | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| US8946185B2 (en) * | 2010-06-18 | 2015-02-03 | Lsip, Llc | Agent for suppressing expression of dominant allele |
| WO2013063536A1 (en) | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| SMT201800092T1 (it) * | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| JPWO2014051109A1 (ja) | 2012-09-28 | 2016-08-25 | 協和発酵キリン株式会社 | 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015152183A1 (ja) * | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| CN114014930A (zh) * | 2015-02-13 | 2022-02-08 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| KR20170140318A (ko) | 2015-04-29 | 2017-12-20 | 리제너론 파마슈티칼스 인코포레이티드 | 진행성 골화성 섬유이형성증의 치료 |
-
2015
- 2015-09-10 US US14/850,844 patent/US20160075772A1/en not_active Abandoned
- 2015-09-11 TW TW104130079A patent/TWI688402B/zh active
- 2015-09-14 SI SI201530852T patent/SI3191512T1/sl unknown
- 2015-09-14 JP JP2017513774A patent/JP6560341B2/ja active Active
- 2015-09-14 AU AU2015315829A patent/AU2015315829B2/en active Active
- 2015-09-14 ME MEP-2019-279A patent/ME03541B/me unknown
- 2015-09-14 LT LTEP15775835.0T patent/LT3191512T/lt unknown
- 2015-09-14 MY MYPI2017700819A patent/MY179654A/en unknown
- 2015-09-14 KR KR1020177009673A patent/KR102564079B1/ko active Active
- 2015-09-14 HR HRP20191929TT patent/HRP20191929T1/hr unknown
- 2015-09-14 CN CN201580049029.1A patent/CN107106648B/zh active Active
- 2015-09-14 ES ES15775835T patent/ES2739605T3/es active Active
- 2015-09-14 MX MX2017003175A patent/MX382026B/es unknown
- 2015-09-14 SM SM20190584T patent/SMT201900584T1/it unknown
- 2015-09-14 MA MA40621A patent/MA40621B1/fr unknown
- 2015-09-14 CA CA2960950A patent/CA2960950C/en active Active
- 2015-09-14 IL IL251063A patent/IL251063B/en unknown
- 2015-09-14 RS RSP20191331 patent/RS59412B1/sr unknown
- 2015-09-14 EP EP19177741.6A patent/EP3604335A1/en not_active Withdrawn
- 2015-09-14 EP EP15775835.0A patent/EP3191512B1/en active Active
- 2015-09-14 PT PT15775835T patent/PT3191512T/pt unknown
- 2015-09-14 NZ NZ730773A patent/NZ730773A/en unknown
- 2015-09-14 SG SG11201701913SA patent/SG11201701913SA/en unknown
- 2015-09-14 SG SG10201902175RA patent/SG10201902175RA/en unknown
- 2015-09-14 PL PL15775835T patent/PL3191512T3/pl unknown
- 2015-09-14 DK DK15775835.0T patent/DK3191512T3/da active
- 2015-09-14 HU HUE15775835A patent/HUE046558T2/hu unknown
- 2015-09-14 WO PCT/US2015/000100 patent/WO2016039796A2/en not_active Ceased
-
2017
- 2017-03-10 CL CL2017000603A patent/CL2017000603A1/es unknown
- 2017-03-27 ZA ZA2017/02112A patent/ZA201702112B/en unknown
- 2017-08-28 US US15/688,740 patent/US20180111983A1/en not_active Abandoned
-
2018
- 2018-10-17 CL CL2018002962A patent/CL2018002962A1/es unknown
-
2019
- 2019-09-17 CY CY20191100972T patent/CY1122188T1/el unknown
- 2019-09-23 US US16/579,126 patent/US11407822B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099683A (es) | Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos. | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| JP6609784B2 (ja) | 治療のためのｃｄ３０×ｃｄ１６抗体とｐｄ−１アンタゴニストとの組み合わせ | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| WO2016039796A3 (en) | Treatment of fibrodysplasia ossificans progressiva | |
| MX2021003436A (es) | Anticuerpos humanos para pd-1. | |
| MX2018014950A (es) | Terapia de combinacion. | |
| MX2020002880A (es) | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). | |
| EA201170157A1 (ru) | Notch-связывающие агенты и антагонисты и способы их применения | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| EA201791171A1 (ru) | Антитела к tigit | |
| WO2008105886A3 (en) | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| MXPA06012601A (es) | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. | |
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| MX2022006147A (es) | Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1. | |
| EA202190495A1 (ru) | Антитела против pd-l1 человека | |
| Mazor et al. | Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1 | |
| US12162932B2 (en) | Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs | |
| US20180030124A1 (en) | Methods and compositions for enhancing anti-ssea4 immunotherapy | |
| EP3091031A1 (en) | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor | |
| JP2009502206A (ja) | 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療 | |
| WO2015191610A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways | |
| Ford | Sizing Up the Competition: Fc-Mediated Effector Functions of Immune Therapeutics Impaired During Chronic Viral Infection | |
| PH12017500470A1 (en) | Treatment of fibrodysplasia ossificans progressiva | |
| HK1228406A1 (en) | Human antibodies to pd-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2024 BY ANAQUA SERVICES Effective date: 20230823 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2025 BY ANAQUA SERVICES Effective date: 20240820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2026 BY ANAQUA SERVICES Effective date: 20250820 |